Literature DB >> 19584499

Probiotics.

V Gupta1, R Garg.   

Abstract

The term "probiotic" was first used in 1965, by Lilly and Stillwell, to describe substances secreted by one organism which stimulate the growth of another. The use of antibiotics, immunosuppressive therapy and irradiation, amongst other means of treatment, may cause alterations in the composition and have an effect on the GIT flora. Therefore, the introduction of beneficial bacterial species to GI tract may be a very attractive option to re-establish the microbial equilibrium and prevent disease. Prebiotic is a non-digestible food ingredient that confers benefits on the host by selectively stimulating one bacterium or a group of bacteria in the colon with probiotic properties. Both probiotics and prebiotics are together called as Synbiotics. Various bacterial genera most commonly used in probiotic preparations are Lactobacillus, Bifidobacterium, Escherichia, Enterococcus, Bacillus and Streptococcus . Some fungal strains belonging to Saccharomyces have also been used. Probiotics have been shown to be effective in varied clinical conditions- ranging from infantile diarrhoea, necrotizing enterocolitis, antibiotic-associated diarrhoea, relapsing Clostridium difficle colitis, Helicobacter pylori infections, inflammatory bowel disease to cancer, female uro-genital infection and surgical infections. Lactobacillus rhamnosus strain GG has proven beneficial affects on intestinal immunity. It increases the number of IgA and other immunoglobulins secreting cells in the intestinal mucosa. It also stimulates local release of interferons. It facilitates antigen transport to underlying lymphoid cells, which serves to increase antigen uptake in Peyer's patches. Probiotics are live microorganisms, so it is possible that they may result in infection in the host. The risk and morbidity of sepsis due to probiotic bacteria should be weighed against the potential for sepsis due to more pathological bacteria and the morbidity of diseases for which probiotic bacteria are being used as therapeutic agents. Also, future, well-designed placebo controlled studies with validated results are required for ascertaining the true health benefits of probiotics The important point in this regard is careful selection of the probiotic agent, its dose standardization and a thorough knowledge of its beneficial effects.

Entities:  

Mesh:

Year:  2009        PMID: 19584499     DOI: 10.4103/0255-0857.53201

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  47 in total

1.  Effects of Lactobacillus plantarum A7 with probiotic potential on colon cancer and normal cells proliferation in comparison with a commercial strain.

Authors:  Hojjat Sadeghi-Aliabadi; Fatemeh Mohammadi; Hossain Fazeli; Maryam Mirlohi
Journal:  Iran J Basic Med Sci       Date:  2014-10       Impact factor: 2.699

2.  Evaluation of the efficacy of probiotics in plaque reduction and gingival health maintenance among school children - A Randomized Control Trial.

Authors:  R Muthu Karuppaiah; S Shankar; S Krishna Raj; K Ramesh; R Prakash; M Kruthika
Journal:  J Int Oral Health       Date:  2013-10-26

3.  Survey and Systematic Literature Review of Probiotics Stocked in Academic Medical Centers within the United States.

Authors:  Andrew M Abe; Philip J Gregory; Darren J Hein; Zara Risoldi Cochrane; Amy F Wilson
Journal:  Hosp Pharm       Date:  2013-11

Review 4.  Cholesterol-Lowering Effects of Lactobacillus Species.

Authors:  Aditi Khare; Smriti Gaur
Journal:  Curr Microbiol       Date:  2020-02-04       Impact factor: 2.188

Review 5.  The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?

Authors:  M Andrea Azcárate-Peril; Michael Sikes; José M Bruno-Bárcena
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-23       Impact factor: 4.052

Review 6.  Therapeutical use of probiotic formulations in clinical practice.

Authors:  T Iannitti; B Palmieri
Journal:  Clin Nutr       Date:  2010-06-23       Impact factor: 7.324

7.  Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice.

Authors:  Seema Saksena; Sonia Goyal; Geetu Raheja; Varsha Singh; Maria Akhtar; Talat M Nazir; Waddah A Alrefai; Ravinder K Gill; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-24       Impact factor: 4.052

8.  Lipoteichoic acid isolated from Lactobacillus plantarum suppresses LPS-mediated atherosclerotic plaque inflammation.

Authors:  Joo Yun Kim; Hangeun Kim; Bong Jun Jung; Na-Ra Kim; Jeong Euy Park; Dae Kyun Chung
Journal:  Mol Cells       Date:  2013-02-21       Impact factor: 5.034

9.  Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.

Authors:  Gamze Demirel; Istemi Han Celik; Omer Erdeve; Sibel Saygan; Ugur Dilmen; Fuat Emre Canpolat
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

Review 10.  Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis.

Authors:  Maurizio Bellavia; Giovanni Tomasello; Marcello Romeo; Provvidenza Damiani; Attilio I Lo Monte; Luciano Lozio; Claudia Campanella; Antonella Marino Gammazza; Francesca Rappa; Giovanni Zummo; Massimo Cocchi; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello
Journal:  Med Microbiol Immunol       Date:  2013-07-18       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.